Regeneron beats quarterly estimates on eczema drug demand; launches dividend program
Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program, sending its shares up 2.2% premarket. U.S. sales of Eylea, which has been its long-standing cash cow, rose by 2% to $1.5 billion, including $305 million from the higher 8-milligram dose version. Analysts were expecting $1.77 billion in total Eylea sales, according to LSEG data.